Aura Biosciences, Inc. (AURA) compared with its closest peers (ODTX, SANA, CADL, SLDB, FDMT). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $1.19B | — |
| Sana Biotechnology, Inc. (SANA) | $1.12B | -4.2 |
| Candel Therapeutics, Inc. (CADL) | $944.24M | -7.8 |
| Solid Biosciences Inc. (SLDB) | $894.91M | -2.8 |
| 4D Molecular Therapeutics, Inc. (FDMT) | $887.29M | -3.1 |
| Allogene Therapeutics, Inc. (ALLO) | $721.37M | -1.6 |
| Tectonic Therapeutic, Inc. (TECX) | $678.35M | -5.1 |
| Prime Medicine, Inc. (PRME) | $583.39M | -2.6 |
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $582.00M | — |
| Artiva Biotherapeutics, Inc. (ARTV) | $543.66M | -1.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
AURA overview · AURA earnings · AURA financials · AURA KPIs · AURA investor relations · AURA ownership · AURA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.